Creating Cures with AI: Redefining the Future of Medicine

CreateCured is a pioneering therapeutics company that leverages the capabilities of artificial intelligence and state-of-the-art pharmaceutical technologies to develop groundbreaking therapies aimed at curing diseases.

Targeting Undruggable Targets

By utilizing our innovative AI-driven drug discovery platform, we have successfully devised novel treatments targeting previously undruggable targets such as TP53, KRAS, and TERT. Our approach promises to fundamentally transform the treatment landscape for areas like oncology and autoimmune disorders.

CY01 for TP53 mutation

  • High lethality: Lethality rate > 90%
  • No resistance: Treatment remains effective even when administered to surviving cells
  • High safety: No lethality to normal cells

HCC TP53 mutation – CDX liver orthotopic induction mouse model (i.v.)

Systemic administration inhibits orthotopic tumor growth.The inhibition efficiency of the tumor is significantly dose-dependent, with medium to high doses significantly inhibiting tumor growth.

  • High inhibition rate: In the high-dose group, the editing efficiency in the tumor reached 87%, with an inhibition rate > 90%.
  • No side effects: No liver toxicity or weight loss observed.
  • No resistance in vivo: Continued administration remains effective, consistent with in vitro results.

Who We Are?​

CreateCured Biotechnology Technology, established in 2024 and headquartered in Shanghai’s Zhangjiang Hi-Tech Park. Founded by industry veterans with decades of combined experience, we’re driven by a singular vision: Pioneering Curative Therapies for Disease.